Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer

Saudi Medical Journal

Volumn 33, Issue 1, 2012, Pages 24-29

  Li, Jin Ming ^a   Zhao, Rong Hua ^a   Li, Shao Tang ^a   Xie, Cai Xia ^a   Jiang, Hong Hua ^a   Ding, Wen Jun ^a   Du, Peng ^a   Chen, Wei ^a   Yang, Ming ^a   Cui, Long ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 143; MICRORNA 145; MICRORNA 21; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FECES; FEMALE; GENE EXPRESSION; HUMAN; MALE; RETROSPECTIVE STUDY;

AGED; COLORECTAL NEOPLASMS; DOWN-REGULATION; FECES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84863045238     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Wan DS. [Epidemiological trend and control strategy of colorectal cancer in China]. Zhonghua Zhong Liu Za Zhi 2011; 33: 481-483. Chinese.
4. Chan YH, Schooling CM. Performance of immunochemical fecal occult blood tests among users of low-dose aspirin. JAMA 2011; 305: 1093-1094.
5. Foo AS, Thia JJ, Ng ZP, Fong NP, Koh GC. Colorectal Cancer Screening: The Effectiveness of Education on Its Barriers and Acceptability. Asia Pac J Public Health 2011. [Epub ahead of print]
6. Szajda SD, Snarska J, Jankowska A, Roszkowska-Jakimiec W, Puchalski Z, Zwierz K. Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients. Hepatogastroenterology 2008; 55: 388-393.
7. Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y. Microarray analysis of micro-ribonucleic acid expression in primary immunoglobulin A nephropathy. Saudi Med J 2008; 29: 1388-1393.
8. Huang Y, Shen XJ, Zou Q, Zhao QL. Biological functions of microRNAs. Bioorg Khim 2010; 36: 747-752.
9. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011; 1812: 592-601.
10. Felekkis K, Touvana E, Stefanou Ch, Deltas C. MicroRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 2010; 14: 236-240.
11. Janakiram NB, Rao CV. Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin 2008; 29: 1-20.
12. Wu XM, Shao XQ, Meng XX, Zhang XN, Zhu L, Liu SX, et al. Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011; 32: 259-269.
13. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 2012; 130: 611-621. [Epub ahead of print]
14. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010; 127: 2870-2878.
15. Zen K, Zhang CY. Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2010 Nov 9. [Epub ahead of print]
16. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feedforward pathway. Genes Dev 2010; 24: 2754-2759.
17. Kitade Y, Akao Y. MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci 2010; 114: 276-280.
18. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther 2010; 17: 398-408.
19. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79: 313-320.
20. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
21. Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009; 6: 281-295.
22. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1766-1774.
23. Ratto C, Ricci R. Potential pitfalls concerning colorectal cancer classification in the seventh edition of the AJCC Cancer Staging Manual. Dis Colon Rectum 2011; 54: e232.
24. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009, 9: 374.
25. Song B, Ju J. Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. Expert Rev Mol Med 2010; 12: 33.